Common pharmacophore of structurally distinct small-molecule inhibitors of intracellular retrograde trafficking of ribosome inactivating proteins

Scientific Reports

Volumn 3, Issue , 2013, Pages

  Yu, Shichao ^a   Park, Jewn Giew ^a   Kahn, Jennifer Nielsen ^b   Tumer, Nilgun E ^b   Pang, Yuan Ping ^a  

^a MAYO CLINIC   (United States)

^b The State University of New Jersey   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MOLECULAR LIBRARY; RIBOSOME INACTIVATING PROTEIN; RICIN;

ANIMAL; CELL LINE; CHLOROCEBUS AETHIOPS; DRUG EFFECTS; METABOLISM; MOLECULAR LIBRARY; PHARMACOLOGY; PROTEIN TRANSPORT; STEREOISOMERISM; VERO CELL LINE;

ANIMALS; CELL LINE; CERCOPITHECUS AETHIOPS; PROTEIN TRANSPORT; RIBOSOME INACTIVATING PROTEINS; RICIN; SMALL MOLECULE LIBRARIES; STEREOISOMERISM; VERO CELLS;

EID: 84889029045     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep03397     Document Type: Article

References (29)

1. Audi, J., Belson, M., Patel, M., Schier, J. & Osterloh, J. Ricin poisoning: a comprehensive review. JAMA 294, 2342-2351 (2005).
2. Liu, Y.-N. et al. Shiga toxin type 2 (Stx2), a potential agent of bioterrorism, has a short distribution and a long elimination half-life, and induces kidney and thymus lesions in rats. Arch. Toxicol. 85, 1133-1140 (2011).
3. Frank, C. et al. Epidemic profile of Shiga-toxin-producing Escherichia coli O104:H4 outbreak in Germany. N. Engl. J. Med. 365, 1771-1780 (2011).
4. Johannes, L. & Römer, W. Shiga toxins-from cell biology to biomedical applications. Nat. Rev. Microbiol. 8, 105-116 (2010).
5. Pang, Y.-P. et al. Small-molecule inhibitor leads of ribosome- inactivating proteins developed using the doorstop approach. PLoS One 6, e17883 (2011).
6. Stechmann, B. et al. Inhibition of retrograde transport protects mice from lethal ricin challenge. Cell 141, 231-242 (2010).
7. Park, J. G., Kahn, J.N., Tumer, N. E.& Pang, Y. P. Chemical structure of Retro-2, a compound that protects cells against ribosome-inactivating proteins. Sci. Rep. 2, 631 (2012).
8. Chinigo, G. M. et al. Asymmetric synthesis of 2,3-dihydro-2- arylquinazolin-4-ones: methodology and application to a potent fluorescent tubulin inhibitor with anticancer activity. J. Med. Chem. 51, 4620-4631 (2008).
9. Cheng, X., Vellalath, S., Goddard, R. & List, B. Direct catalytic asymmetric synthesis of cyclic aminals from aldehydes. J. Am. Chem. Soc. 130, 15786-15787 (2008).
10. Rueping, M., Antonchick, A. P., Sugiono, E.& Grenader, K. Asymmetric Brønsted acid catalysis: catalytic enantioselective synthesis of highly biologically active dihydroquinazolinones. Angew. Chem. Int. Ed. 48, 908-910 (2009).
11. Prakash, M. & Kesavan, V. Highly enantioselective synthesis of 2,3-dihydroquinazolinones through intramolecular amidation of imines. Org. Lett. 14, 1896-1899 (2012).
12. Cheng, D.-J., Tian, Y. & Tian, S.-K. Catalytic asymmetric synthesis of dihydroquinazolinones from imines and 2-aminobenzamides. Adv. Synth. Catal. 354, 995-999 (2012).
13. Hyun, M. H. & Pirkle, W. H. Liquid chromatographic separation of the stereoisomers of thiazide diuretics. J. Chromatogr. A 876, 221-227 (2000).
14. Chankvetadze, B., Yashima, E. & Okamoto, Y. Dimethyl-, dichloro-and chloromethylphenylcarbamates of amylose as chiral stationary phases for highperformance liquid chromatography. J. Chromatogr. A 694, 101-109 (1995).
15. Hisano, T., Ichikawa, M., Nakagawa, A. & Tsuji, M. Studies on organosulfur compounds XII: syntheses and pharmacological activities of 2-heterocyclic substituted 4(3H)-quinazolinones. Chem. Pharm. Bull. 23, 1910-1916 (1975).
16. Cohen, E., Klarberg, B. & Vaughan, J. R. Quinazolinone sulfonamides as diuretic agents. J. Am. Chem. Soc. 81, 5508-5509 (1959).
17. Yale, H. L. & Kalkstein, M. Substituted 2,3-dihydro-4(1H)- quinazolinones. A new class of inhibitors of cell multiplication. J. Med. Chem. 10, 334-336 (1967).
18. Bonola, G., DaRe, P., Magistretti, M. J., Massarani, E. & Setnikar, I. l-Aminoacyl-2,3-dihydro-4(1H)-quinazolinoiie derivatives with choleretic and antifibrillatory activity. J. Med. Chem. 11, 1136-1139 (1968).
19. Okumura, K., Oine, T., Yamada, Y., Hayashi, G. & Nakama, M. 4-Oxo-1,2,3,4-tetrahydroquinazolines. I. Syntheses and pharmacological properties of 2-methyl-3-aryl-4-oxo-1,2,3,4-tetrahydroquinazolines and their 1-acyl derivatives. J. Med. Chem. 11, 348-352 (1968).
20. Alaimo, R. J. & Russell, H. E. Antibacterial 2,3-Dihydro-2-(5-nitro- Zthieny1)-quinazolin-4(1H)-one. J. Med. Chem. 15, 335-336 (1972).
21. Neil, G. L., Li, L. H., Buskirk, H. H. & Moxley, T. E. Antitumor effects of the antispermatogenic agent, 2,3-dihydro-2-(1-naphthyl)-4(1H)- quinazolinone (NSC-145669). Cancer Chemother. Rep. 56, 163-173 (1972).
22. Levin, J. I., Chan, P. S., Bailey, T., Katocs, A. S. & Venkatesan, A. The synthesis of 2,3-dihydro-4(1H)-quinazolinone angiotensin II receptor antagonists. Bioorg. Med. Chem. Lett. 4, 1141-1146 (1994).
23. Hour, M. J. et al. 6-Alkylamino-and 2,3-dihydro-39-methoxy-2-phenyl-4- quinazolinones and related compounds: their synthesis, cytotoxicity, and inhibition of tubulin polymerization. J. Med. Chem. 43, 4479-4487 (2000).
24. Noel, R. et al. N-methyldihydroquinazolinone derivatives of Retro-2 with enhanced efficacy against Shiga toxin. J. Med. Chem. 56, 3404-3413 (2013).
25. Saenz, J. B., Doggett, T. A. & Haslam, D. B. Identification and characterization of small molecules that inhibit intracellular toxin transport. Infect. Immun. 75, 4552-4561 (2007).
26. Wang, Q. & Pang, Y.-P. Preference of small molecules for local minimum conformations when binding to proteins. PLoS ONE 2, e820 (2007).
27. Wang, Q. & Pang, Y.-P. Normal-mode-analysis-monitored energy minimization procedure for generating small-molecule bound conformations. PLoS ONE 2, e1025 (2007).
28. Frisch, M. J. et al. GAUSSIAN 98, Revision A.7. Gaussian, Inc. Pittsburgh, PA (1999).
29. Jacewicz, M., Feldman, H. A., Donohue-Rolfe, A., Balasubramanian, K. A. & Keusch, G. T. Pathogenesis of Shigella diarrhea. XIV. Analysis of Shiga toxin receptors on cloned HeLa cells. J. Infect. Dis. 159, 881-889 (1989). Diseases